Prime award
AURAVAX THERAPEUTICS, INC. · Department of Health and Human Services
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
Current value$750K
Obligated to date$0
Months remaining3
Sign in to mark this as watching, pursuing, or passed — and to be told when its end date changes.
Recompete signal
This award ends in 3 months and drew a single offer last time.
Award record
| Field | Value |
|---|---|
| Recipient | AURAVAX THERAPEUTICS, INC. |
| Awarding agency | Department of Health and Human Services |
| NAICS | 541714 |
| PSC | AN14 |
| Place of performance | TX |
| Period | → Dec 31, 2026 |
| Set-aside | NO SET ASIDE USED. |
| Competition | A |
| Offers received | 1 offer |
| Vehicle | Standalone |
Data & sources
Record as published by USAspending.gov, vintage FY2021–FY2025 full archives · USAspending.gov, retrieved Aug 6, 2026. Values change as modifications are reported; obligations may be negative when work is de-obligated.